ArticleContact dermatitis2026
Patch Test Results With Additions to the European Baseline Series, 2021/22-Joint European Results of the ESSCA
Article in Contact dermatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundAllergens are periodically added to the European Baseline Series (EBS) to audit their value in consecutive patch testing.
objectivesTo present results of audit allergens tested in consecutive patients in 54 departments in 13 European countries during 2021 and 2022.
methodsAnonymized or pseudonymized individual data, and partly aggregated data on patch test rest results and their clinical relevance were prospectively collected and centrally pooled and analyzed.
resultsIn 2021 and 2022, 18 832 patients were patch tested with the EBS, and 2860 with the TRUE Test baseline series (supplemented with some missing EBS allergens). Of these patients, 17 359 were additionally tested with one or more of the 19 audit allergen preparations examined. Apart from the terpene hydroperoxides (OOH) which yielded the highest numbers of positive patch test reactions (linalool-OOH 1% pet.: 7.65 (7.09%-8.23%) [95% CI] and limonene-OOH 0.3% pet. 6.78 (6.26%-7.32%)), positive reactions were most often seen to benzisothiazolinone (3.71 (3.3%-4.15%)), sodium metabisulfite (3.49 (3.14%-3.88%)), Evernia furfuracea (tree moss, 1.79 (1.4%-2.26%)), and decyl and lauryl glucoside, at 1.49 (1.25%-1.76%) and 1.26 (1.05%-1.51%), respectively. The other allergens yielded around 1% or fewer positive patch test reactions. Clinical relevance varied, with Evernia furfuracea, 2-bromo-2-nitropropane-1,3-diol and terpene hydroperoxides considered relevant in more than 2/3 cases, while for other frequent sensitizers benzisothiazolinone and sodium metabisulfite, relevance could be confirmed in half of the cases or less often.
conclusionsThe current results, along with other published data, will serve to inform decisions concerning possible revision of the EBS, considering frequency of positive reactions, their clinical relevance and the overall reaction profile of each of the allergens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.